Preparation method and application of a composition for promoting cartilage and new bone regeneration
Through the composition of calcium-based meteorite ceramic powder and pharmaceutical excipients, the problem of cell therapeutic agent distribution and planting difficulties in cartilage defects is solved, significantly improving the regeneration ability of cartilage and new bone, and improving joint synovial membrane and vascular hyperplasia .
Patent Information
- Application Number
- CN202410972442.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-19
AI Technical Summary
Existing cell therapeutic agents are difficult to distribute and transplant evenly in the cartilage defect site, resulting in reduced chondrocyte regeneration and difficult to promote the regeneration of cartilage and new bone.
Using calcium-based meteorite ceramic powder (Ca-MCP) and medically acceptable pharmaceutical excipients, a composition that promotes cartilage and new bone regeneration is prepared by mixing and processing. The mass percentage of Ca-MCP is 0.1-10%, and make it into suitable dosage forms for regeneration of cartilage and new bone.
It significantly improves the expression of BMP-2, BMP-4, and BMP-7 in the serum, improves synovial hyperplasia, invasive inflammatory cell infiltration and vascular hyperplasia, and has the ability to promote new bone regeneration of cartilage.
Smart Images

Figure CN118662528B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical repair and regeneration materials, and particularly relates to a preparation method and application of a composition for promoting the regeneration of cartilage and new bone. Background Art
[0002] Osteoarthritis (OA) is a disease characterized by local degenerative changes as articular cartilage wears away, mainly affecting articular cartilage, subchondral bone, synovium, joint capsule and other structures of the joint. It is the leading cause of joint pain and disability in the elderly.
[0003] Articular cartilage is mainly composed of chondrocytes and cartilage matrix. It is a special connective tissue that is smooth and elastic, and has the functions of lubricating joints and absorbing shocks. Modern medicine believes that there is only one type of cell in articular cartilage, namely chondrocytes, which are involved in the metabolism and repair of cartilage. Western medicine believes that articular cartilage tissue hypoxia caused by various reasons, or insufficient local blood supply to cartilage due to increased blood viscosity, etc., will affect the degeneration process of articular cartilage. In addition, abnormal blood circulation function of cartilage will lead to the gradual thickening of the subchondral bone plate and abnormal cancellous bone structure.
[0004] In previous in vitro experiments on the use of traditional Chinese medicine to treat KOA, it has been confirmed that the biosynthesis of chondrocytes is related to a variety of cytokines and bioactive molecules. Related studies have shown that a variety of cells and inflammatory factors (such as TGF-β, IL-1, IL-6, TNF-α, etc.) can activate the Rho / Rock signaling pathway to participate in the metabolism of chondrocytes. Among them, inflammatory mediators such as IL-1, IL-6, TNF-α can stimulate cartilage and synovial cells to release negative regulatory factors such as PGE2 and MMP-3, causing the cartilage matrix to degrade at a faster rate, thereby accelerating the degeneration of cartilage; and the release group of BMP-related regulatory factors is conducive to the recovery and regeneration of articular cartilage.
[0005] The cause of degenerative changes in articular cartilage is not yet clear, but one known cause is the absolute reduction in the number of chondrocytes and the imbalance between the synthesis and decomposition of cartilage matrix in chondrocytes. Therefore, degenerative changes in articular cartilage are due to the decomposition of cartilage matrix, which reduces the strength of cartilage and its function as a cushion.
[0006] The disadvantage of existing cell therapy agents is that the transplanted cells gather in one direction due to gravity, making it difficult to evenly distribute in the defect site, making it difficult for the cells to be transplanted and engrafted, which reduces the cell regeneration in the cartilage defect. At the same time, the transplanted cells are difficult to evenly distribute and engraft in the defect site due to gravity, inducing differentiation into fibrocartilage instead of hyaline cartilage, and the cartilage will be fragile in the later stage. Therefore, it is urgent to develop a composition that can effectively promote cell regeneration and new bone regeneration in cartilage defects. Summary of the invention
[0007] In view of the problems existing in the above-mentioned prior art, the object of the present invention is to provide a method for preparing a composition for promoting the regeneration of cartilage and new bone and its application.
[0008] In order to achieve the above technical objectives, the present invention provides the following technical solutions:
[0009] The first aspect of the present invention provides a composition for promoting cartilage and new bone regeneration, comprising calcium-based meteorite ceramic powder (hereinafter abbreviated as Ca-MCP) and medically acceptable pharmaceutical excipients, wherein the mass percentage of the calcium-based meteorite ceramic powder is 0.1 to 10%.
[0010] Preferably, the lead dissolution of the Ca-MCP is less than 0.1 mg / L, and the cadmium dissolution is less than 0.02 mg / L.
[0011] Preferably, the Ca-MCP is made by mixing achondrite, purple sand and clay in certain mass percentages, and the mass percentages of the achondrite, purple sand and clay are 0.3-43%: 56-95%: 1-5%.
[0012] The Ca-MCP mentioned in the present invention is prepared by a method for preparing a meteorite ceramic with ultra-low heavy metal dissolution and low radioactivity disclosed in a Chinese patent application authorization announcement number: CN 107586098B.
[0013] Preferably, the medically acceptable pharmaceutical excipient is selected from one or a combination of two or more of menthol, liquid paraffin, xanthan gum, cetearyl glucoside, cetearyl alcohol, butylene glycol, glycerol, monoglyceride, polydimethylsiloxane, and menthone glycerol ketal.
[0014] Preferably, the dosage form of the composition is any one of lotion, liniment, tincture, oil, ointment, plaster, paste, patch, film, gel, spray, emulsion, lyophilized powder, aerosol, and tablet.
[0015] The second aspect of the present invention provides a method for preparing the above-mentioned composition for promoting cartilage and new bone regeneration, the method comprising: mixing Ca-MCP with a medically acceptable pharmaceutical excipient to obtain the composition.
[0016] The third aspect of the present invention provides the use of the above composition in the preparation of a drug for promoting cartilage and new bone regeneration.
[0017] The present invention has the following beneficial effects:
[0018] (1) The present invention provides a composition for promoting cartilage and new bone regeneration, comprising calcium-based meteorite ceramic powder (Ca-MCP) and medically acceptable pharmaceutical excipients, wherein the mass percentage of Ca-MCP is 0.1-10%. The composition has a certain promoting effect on increasing BMP-2, BMP-4, and BMP-7 in serum, and has a significant improvement effect on joint synovial hyperplasia, inflammatory cell infiltration, and vascular hyperplasia, and has a certain ability to promote the regeneration of cartilage and new bone.
[0019] (2) The composition provided by the present invention can be used in the preparation of drugs for tissue engineering cartilage, bone repair and regeneration, and wound repair. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0021] Figure 1 The pictures of light microscopy results are as follows: (a) normal group; (b) model group; (c) positive drug (sodium hyaluronate) group; (d) treatment group;
[0022] Figure 2 This is the result of Western blot detection. DETAILED DESCRIPTION
[0023] In the following description, specific details such as specific system structures, technologies, etc. are provided for the purpose of illustration rather than limitation, so as to provide a thorough understanding of the embodiments of the present invention. However, it should be clear to those skilled in the art that the present invention may be implemented in other embodiments without these specific details. In other cases, detailed descriptions of well-known systems, devices, circuits, and methods are omitted to prevent unnecessary details from obstructing the description of the present invention.
[0024] Example 1
[0025] A composition for promoting cartilage and new bone regeneration, comprising Ca-MCP and medically acceptable pharmaceutical excipients, specifically: polydimethylsiloxane, cetearyl alcohol, monoglyceride, liquid paraffin, menthone glycerol acetal, glycerol, xanthan gum. The composition is made into an ointment, and the steps are as follows:
[0026] S1. Preparation of Ca-MCP:
[0027] S11. Material selection and grinding: prepare raw materials according to the following components: achondrite, purple sand, and clay; grind the achondrite into 200-mesh powder, grind the purple sand into 200-mesh powder, and grind the clay into 200-mesh powder;
[0028] S12, slurry preparation: dry the three raw materials in step S1, weigh 0.3g of achondrite, 95g of purple sand, and 4.7g of clay, mix them thoroughly, add 20g of water to prepare the slurry, and the Zn content in the slurry preparation water is more than 0.7mg / L, and the β radioactivity is less than 0.03Bq / L;
[0029] S13, kneading the clay: repeatedly kneading, beating and squeezing the mixture after slurry preparation in step S2 until the cross section of the clay is shiny;
[0030] S14, aging: the mixture obtained in step S3 is placed in a sealed stainless steel container and allowed to stand for 3 months;
[0031] S15, re-kneading the mud: kneading, beating, and squeezing the mixed material obtained in step S4 again to knead the mud;
[0032] S16, molding: the mixed material obtained in step S5 is manually molded;
[0033] S17, drying: drying the embryo formed in step S6 in the shade;
[0034] S18, drying: after loading the dried embryo body in step S7 into a kiln, heat it to 100°C in 2 hours, keep it for 2 hours, then heat it to 200°C in 40 minutes, keep it at 200°C for 1 hour, cool it naturally, take out the embryo body and repair it;
[0035] S19, sintering: raise the temperature to 200°C in 1 hour, then raise the temperature to 500°C in 1.5 hours, keep it for 20 minutes, then raise the temperature to 700°C in 40 minutes, keep it for 20 minutes to make it crystallize, then raise the temperature to 1160°C in 1 hour and 40 minutes, keep it for 0.5 hour, turn off the flame, open the damper and cool it naturally to 700°C, close the damper, open the damper again when the temperature drops to 500°C, and when it drops below 160°C, half-open the kiln door for ventilation and cooling until it is taken out of the kiln to obtain Ca-MCP.
[0036] S2, 1.5g of polydimethylsiloxane, 1.1g of cetearyl alcohol, and 0.5g of monoglyceride were mixed evenly, and then added to 15g of melted liquid paraffin, mixed evenly, and an oil phase was obtained; 5g of menthone glyceryl acetal and 8g of glycerol were added to 20g of water to dissolve, and then 10g of xanthan gum was added, heated, and mixed evenly to obtain an aqueous phase; finally, 8.9g of the Ca-MCP prepared in step S1 and the oil phase were added stepwise to the aqueous phase, mixed evenly, and a light yellow composite ointment was obtained;
[0037] 1. Animal experiments
[0038] 1.1 Experimental animals: 50 male Sprague-Dawley rats, 8 weeks old, weighing 200-280g (sPF grade, no specific pathogens), provided by the Animal Experiment Center of XX University. They were randomly divided into group A (anterior cruciate ligament transection group, 15 rats), group B (model post-drug administration group, 15 rats), (sham operation group, 5 rats) and group D (positive drug group, 15 rats), and each group was further divided into 3 groups of 2, 6 and 8 weeks (5 rats in each group) according to the time. The left knee joint of each group was the experimental group, and the right side was the control. The experimental rats were evenly housed in cages, free to move, exposed to natural light, and free to eat. The breeding temperature was 20-23℃, and the relative humidity was 50%-55%.
[0039] 1.2 Establishment of animal model
[0040] Group A: Anterior cruciate ligament transection model (ALCT model). Rats were intraperitoneally anesthetized with 30g / L sodium pentobarbital at a dose of 30mg / kg. The knee joint was routinely prepared and disinfected. The left parapatellar medial incision was made to expose the knee joint, the joint capsule was cut, the joint cavity was opened, the patella was dislocated to the outside, the knee joint was flexed as much as possible to expose the anterior cruciate ligament, and the anterior cruciate ligament was cut with a small sharp knife under direct vision. The drawer test was performed to determine the anterior cruciate ligament rupture. The cartilage surface was not damaged during the operation. Hemostasis was thorough, the patella was reset, and the incision was closed layer by layer. The control group was used as a sham operation group. The knee joint was entered in the same way, the joint capsule was cut, the joint cavity was opened, the patella was dislocated, the knee joint was flexed to expose the anterior cruciate ligament, the cruciate ligament was not cut, and then the patella was reset and the joint cavity was closed. Rats did not take any fixation measures after surgery, and penicillin 400,000 u was injected intramuscularly once a day for 3 consecutive days.
[0041] 1.3 Administration
[0042] After the model was constructed, drug administration began. The blank group and the model group were smeared with a mixture of equal amounts of excipients used in Example 1 (specifically polydimethylsiloxane, cetearyl alcohol, monoglyceride, liquid paraffin, menthone glycerol acetal, glycerol, xanthan gum) and physiological saline on the knee joint; positive drug (sodium hyaluronate) group: sodium hyaluronate was injected into the knee joint cavity of rats, once a week (0.5 ml / side / time); treatment group: after the rats were anesthetized by isoflurane inhalation, the hair on the surface of the knee joint was removed with a depilatory cream to expose the skin, and the composition ointment prepared in Example 1 was evenly applied to cover the surface of the knee joint. After absorption for 10 minutes, the animals were restored to consciousness, twice a day for 2 weeks.
[0043] 1.4 ELISA detection of BMP-2, BMP-4, BMP-7 The experimental group animals (group A and group B) were treated with the composition ointment prepared in Example 1 at 2, 6 and 8 weeks after modeling. Two weeks later, the animals were killed by cervical dislocation, and the serum was tested for BMP. The results are shown in Table 1 below.
[0044] Table 1. Elisa assay results for BMP-2, BMP-4, and BMP-7 in serum of rats with osteoarthritis (χ±S)
[0045]
[0046] Note: Compared with the model group, the levels of serum BMP-2, BMP-4 and BMP-7 in each group were *P<0.05, **P<0.01; compared with the positive drug group, △<0.05, △△<0.01; compared with the blank group, ▲P<0.05, ▲▲P<0.01.
[0047] As shown in Table 1, after 6 weeks of administration, compared with the blank control group, the expression of BMP-2, BMP-4 and BMP-7 in the serum of the model group was significantly reduced, P<0.05 compared with the blank control group. The expression of BMP-2, BMP-4 and BMP-7 in the sodium hyaluronate group was higher than that in the model group, but lower than that in the treatment group *P<0.05. The expression of BMP-2 and BMP-4 in the treatment group was higher than that in the sodium hyaluronate group, and the expression of BMP-7 in the treatment group was similar to that in the sodium hyaluronate group, but the standard deviation was smaller within the treatment group.
[0048] The content of BMP-2, BMP-4 and BMP-7 in the serum of the above-mentioned model group rats was significantly reduced, which became the reason for the decrease in the ability of subchondral bone formation in early osteoarthritis. The decrease in the ability of cartilage new bone formation led to the localized osteoporosis of subchondral bone in early osteoarthritis, increased the load stress of articular cartilage, and thus aggravated the degeneration of articular cartilage. After treatment, each group played a certain role in improving the content of BMP-2, BMP-4 and BMP-7 in serum. Among them, the sodium hyaluronate commonly used in clinical practice had a certain improvement in the ability of BMP-2 and BMP-4 formation, but it was lower than the treatment group, and the effect on improving the content of BMP-7 was close to that of the treatment group. This shows that the calcium-based meteorite ceramic powder (Ca-MCP) in the composition used in the treatment group is better than sodium hyaluronate in promoting the ability of cartilage new bone formation. After 6 weeks of giving the team a far-infrared analgesic sound, it showed a more significant effect of promoting bone formation.
[0049] 1.5 Collection and processing of light microscopy specimens
[0050] The experimental group animals were killed by cervical dislocation at 2, 6 and 8 weeks after administration, and the weight-bearing part of the medial femoral condyle of the knee joint was removed, routinely decalcified, dehydrated, paraffin-embedded, and sliced for post-optical microscopic observation and immunohistochemical detection. The joint pathology grading and scoring standards are shown in Table 2.
[0051] Table 2. Joint pathology grading criteria
[0052]
[0053]
[0054] 1.6 Histopathological changes of the joints of rats in each group. The results of light microscopy are shown in Figure 1 and Table 3.
[0055] Table 3. Statistical results of pathological changes in joint tissues of each group
[0056]
[0057] Note: Compared with the model group, *P<0.05, **P<0.01, #P<0.1
[0058] Table 3 and Figure 1 The results are shown below:
[0059] Normal group: The joint capsule wall was smooth, the synovial tissue had no congestion or edema, there was no inflammatory cell infiltration in the tissues around the joints, the joint surface was smooth, the chondrocytes were arranged neatly, and the subchondral bone was normal.
[0060] Model group: Microscopically, the synovial membrane of the animal joints showed mild to severe hyperplasia, which extended into the joint cavity in the form of short villi or fingers, and the joint cavity was reduced; there was more fibrous tissue hyperplasia in the tissues around the joints, accompanied by varying degrees of vascular hyperplasia and inflammatory cell infiltration, mainly lymphocytes and mononuclear macrophages; the joint surface was not smooth, and the chondrocytes of some animals fell off in sheets and necrotized, forming ulcers, with hyperplasia of fibrous connective tissue on the ulcer surface and invasion of new blood vessels, which was significantly different from the normal group (P < 0.01).
[0061] Positive drug (sodium hyaluronate) group: Compared with the model group, joint synovial hyperplasia, bone destruction and inflammatory cell infiltration were all alleviated, which indicates that the sodium hyaluronate group has a slight improvement on joint synovial hyperplasia, bone destruction, inflammatory cell infiltration and vascular hyperplasia; the degree of vascular hyperplasia tends to be reduced compared with the model group (P=0.061).
[0062] Treatment group: Microscopically, most animals showed slight or mild synovial hyperplasia, and some animals showed moderate synovial hyperplasia around the joints. A small amount of inflammatory cells and a small amount of vascular hyperplasia were seen in the interstitium, which was significantly reduced compared with the model group (P < 0.05); focal chondrocyte shedding and osteophyte formation were seen on the articular cartilage surface, and a small amount of fibrous tissue hyperplasia was seen under the cartilage, which was significantly reduced compared with the model group, but no statistical difference was found. This shows that the Ca-MCP in the composition used in the treatment group has a significant improvement effect on cell synovial hyperplasia, bone destruction, inflammatory cell infiltration and vascular hyperplasia, has a certain improvement effect on joint bone destruction, and has a certain effect on promoting the regeneration of cartilage and new bone. In addition, by comparing the positive drug (sodium hyaluronate) group and the treatment group, it can be found that the recovery state and movement flexibility of the rats in the treatment group are significantly better than those in the sodium hyaluronate control group.
[0063] 2. WB detection of the expression of molecules BMPR, SMAD1 / 5 / 9, and CREB1
[0064] Bone morphogenetic protein (BMP) (which has the ability to induce endochondral ossification in extra-bone tissue) participates in many biological processes including cell proliferation, differentiation, migration, apoptosis, etc., and plays an important role in the formation of bone and cartilage. BMP participates in a variety of signaling pathway cascades by binding to different receptors, protecting articular cartilage from cartilage destruction caused by inflammation, trauma, etc. BMP alone or in combination with other cytokines can repair cartilage defects and improve degenerative lesions, and promote the differentiation and regeneration of articular chondrocytes. The receptor of BMP is a membrane protein receptor, which completes signal transduction through a cell surface receptor complex, which is composed of two different transmembrane serine / threonine kinase receptors. The signal transduction of BMP is mediated by two receptors, BMPRⅠ and BMPRⅡ, which form a transmembrane serine / threonine kinase receptor complex. The BMPRⅡ receptor with kinase activity phosphorylates the BMPRⅠ receptor in the GS box, and then transmits transcriptional activation signals to the cell. Therefore, the correct regulation of the BMP signaling pathway can promote cell differentiation.
[0065] Osteoblasts (cells differentiated from preosteoblasts, rich in organelles such as endoplasmic reticulum, Golgi apparatus and mitochondria, and can synthesize a large amount of collagen and other bone matrix components. Osteoblasts mainly participate in the development and maintenance of bones through bone formation and bone remodeling) play an important role in the development, repair and metabolism of bones. They participate in the formation, growth and regeneration of bones and maintain the structure and function of bones. The normal function of osteoblasts is precisely regulated by multiple signaling pathways, and plays an important role in various biological processes such as cell fate determination, proliferation, differentiation and apoptosis. In the skeletal system, the bone morphogenetic protein (BMP) signal transduction pathway regulates the differentiation, proliferation and maturation of osteoblasts, as well as the formation and remodeling of bone tissue.
[0066] Studies have shown that the BMP signaling pathway is positively correlated with cartilage tissue regeneration or repair. BMPR (bone morphogenetic protein receptor), SMAD1 / 5 / 9 (drosophila mothers against decapentaplegic protein), and CREB1 (cyclic AMP response element binding protein 1) are the core molecules of the BMP signaling pathway. Therefore, the expression changes of bone proteins were detected to study whether the BMP signaling pathway is involved in the differentiation of osteoblasts and chondrocytes.
[0067] 2.1 Reagent preparation
[0068] (1) SDS-PAGE reagent: see electrophoresis experiment.
[0069] (2) Homogenization buffer: 1.0 M Tris-HCl (pH 6.8) 1.0 ml; 10% SDS 6.0 ml; β-mercaptoethanol 0.2 ml; ddH2O 2.8 ml.
[0070] (3) Transfer buffer: 2.9 g glycine; 5.8 g Tris; 0.37 g SDS; 200 ml methanol; add ddH2O to make up to 1000 ml.
[0071] (4) 0.01M PBS (pH 7.4): NaCl 8.0 g; KCl 0.2 g; Na2HPO4 1.44 g; KH2PO4 0.24 g; add ddH2O to 1000 ml.
[0072] (5) Membrane staining solution: 0.2 g Coomassie brilliant blue; 80 ml methanol; 2 ml acetic acid; 118 ml ddH2O; Coating solution (5% skim milk powder): 1.0 g skim milk powder dissolved in 20 ml 0.01 M PBS.
[0073] (6) Color developing solution: DAB 6.0 mg; 0.01 M PBS 10.0 ml; nickel ammonium sulfate 0.1 ml; H2O2 1.0 μl.
[0074] (7) Preparation of BMPR, SMAD1 / 5 / 9, and CREB1 antibodies;
[0075] 2.2 Extraction of total protein from cartilage tissue:
[0076] (1) Place a small amount of cartilage tissue blocks from each group in the spherical part of a 1-2 ml homogenizer and use clean scissors to cut the tissue blocks into small pieces as much as possible.
[0077] (2) Add 400 μL of single detergent lysis solution (containing PMSF) to the homogenizer and homogenize. Then place on ice.
[0078] (3) Grind again after a few minutes and place on ice. Repeat this process several times to crush the tissue as much as possible.
[0079] (4) After lysis for 30 minutes, transfer the lysate to a 1.5 ml centrifuge tube using a pipette, then centrifuge at 12,000 rpm for 5 minutes at 4°C. Take the supernatant and divide it into 0.5 ml centrifuge tubes and store them at -20°C.
[0080] 2.3 Electrophoresis
[0081] (1) SDS-PAGE gel preparation
[0082] SDS-PAGE gels can be prepared by referring to some literature or using a gel preparation kit. The kit provides all reagents except water and gel preparation equipment, as well as recipes for preparing SDS-PAGE of various concentrations.
[0083] (2) Sample processing
[0084] Add an appropriate amount of concentrated SDS-PAGE protein loading buffer to the collected protein sample. For example, 2X or 5X SDS-PAGE protein loading buffer. Using 5X SDS-PAGE protein loading buffer can reduce the loading volume, and more protein samples can be loaded in the same volume of loading wells. 5X SDS-PAGE protein loading buffer can be prepared by referring to relevant literature, or SDS-PAGE protein loading buffer (5X) (P0015) can be used. Heat at 100℃ or in a boiling water bath for 3-5 minutes to fully denature the protein.
[0085] (3) Sample loading and electrophoresis
[0086] After cooling to room temperature, the protein sample can be directly loaded into the SDS-PAGE gel loading hole. In order to facilitate the observation of electrophoresis and transfer effects, as well as to determine the molecular weight of the protein, it is better to use a prestained protein molecular weight standard (P0066). During electrophoresis, it is usually recommended to use low voltage constant voltage electrophoresis when the upper gel is used, and high voltage constant voltage electrophoresis when bromophenol blue enters the lower gel. For Bio-Rad's standard electrophoresis device or similar electrophoresis devices, the low voltage can be set at 80-100V and the high voltage can be set at around 120V. SDS-PAGE can be performed using an ordinary electrophoresis instrument to meet the requirements, or it can be performed using Biyuntian's multifunctional electrophoresis instrument (with timing) (EEP102). For the convenience of electrophoresis, the constant voltage method can also be used throughout the SDS-PAGE process. Usually, the voltage is set at 100V, and then the timing time is set to 90-120 minutes. Setting the timing can avoid electrophoresis that often occurs. Usually, electrophoresis can be stopped when bromophenol blue reaches the bottom of the gel, or it can be stopped when it is estimated that the target protein has been properly separated based on the electrophoresis of the pre-stained protein molecular weight standard.
[0087] (4) Transfer
[0088] PVDF membrane (FFP36 / FFP39) is used in Western experiments. Nitrocellulose membrane (NC membrane) (FFN06 / FFN09) can also be used, but nitrocellulose membrane is relatively brittle and is easy to crack during operation, especially when clamped with tweezers. Please refer to the manufacturer's recommended usage steps for the use of the membrane. Usually, if you use Bio-Rad's standard wet transfer device, you can set the transfer current to 300-400mA and the transfer time to 30-60 minutes. You can also transfer the membrane overnight at 15-20mA. The specific transfer time depends on the size of the target protein. The larger the molecular weight of the target protein, the longer the transfer time required, and the smaller the molecular weight of the target protein, the shorter the transfer time required.
[0089] During the transfer process, especially when transferring at high current and quickly, there is usually a very serious heating phenomenon. It is better to place the transfer tank in an ice bath for transfer. The effect of transfer can be observed by the pre-stained protein molecular weight standard used. Usually, 1-2 bands with larger molecular weight are difficult to transfer to the membrane. The effect of transfer can also be observed by staining the membrane with Ponceau Red Staining Solution (P0022) to observe the actual transfer effect. You can also use Coomassie Brilliant Blue Fast Staining Solution (P0017) to stain the SDS-PAGE gel after transfer to observe the residual protein.
[0090] (5) Blocking
[0091] After the transfer is completed with the UV crosslinker, immediately place the protein membrane in the pre-prepared Western washing solution (P0023C) and rinse for 1-2 minutes to wash off the transfer solution on the membrane. In all steps after the transfer, be sure to keep the membrane moist and avoid drying the membrane, otherwise it is very easy to produce a high background. Use a micro desktop vacuum pump (EVAC06 / EVAC07) or a dropper to suck out the washing solution, add Western blocking solution (P0023B), shake slowly on a shaker, and block at room temperature for 60 minutes. For some antibodies with high background, you can block at 4°C overnight. The lateral swing speed is relatively slow, and it is also easy for the solution to cover the protein membrane.
[0092] (6) Primary antibody incubation
[0093] Refer to the instructions of the primary antibody and dilute the primary antibody with Western primary antibody diluent (P0023A) in an appropriate ratio. Use a micro-tabletop vacuum pump or dropper to suck out the blocking solution, immediately add the diluted primary antibody, and incubate slowly at room temperature or 4°C on a side-swinging shaker for 1 hour. If the primary antibody incubation for 1 hour is not effective, you can incubate it overnight at 4°C with slow shaking. Or choose the appropriate incubation temperature and time according to the instructions of the antibody. Recover the primary antibody. Add Western washing solution (P0023C) and wash slowly on a side-swinging shaker for 5-10 minutes. After the washing solution is sucked out, add washing solution and wash for 5-10 minutes. Wash 3 times in total. If the background of the result is high, the washing time can be appropriately extended and the number of washes can be increased. Note: Western results usually require an internal reference as a control. Tubulin antibody (AT819) or Actin antibody (AA128) can usually be used for internal reference detection.
[0094] (7) Secondary antibody incubation
[0095] Refer to the instructions of the secondary antibody and dilute the horseradish peroxidase (HRP) labeled secondary antibody with Western secondary antibody diluent (P0023D) in an appropriate ratio. The secondary antibody should be selected according to the primary antibody. For example, if the primary antibody is mouse IgG, the secondary antibody should be anti-mouse IgG, such as horseradish peroxidase labeled goat anti-mouse IgG (H+L) (A0216). Bio-Tech offers a variety of secondary antibodies. Use a micro-tabletop vacuum pump or dropper to suck out the washing solution, immediately add the diluted secondary antibody, and incubate for one hour at room temperature or 4°C on a side-to-side shaker with slow shaking. Recover the secondary antibody. Add Western washing solution (P0023C) and wash for 5-10 minutes on a side-to-side shaker with slow shaking. After sucking out the washing solution, add washing solution and wash for 5-10 minutes. Wash 3 times in total. If the background of the result is high, the washing time can be appropriately extended and the number of washes can be increased.
[0096] (8) Protein detection
[0097] Use ECL reagents such as BeyoECL Plus (P0018) to detect proteins. The film can be pressed using a dedicated film pressing cassette (FFC58 / FFC83). When developing the film, you can use an automatic X-ray film developer. If there is no automatic film developer, you can use the developer and fixer kit (P0019 / P0020) to prepare the developer and fixer for manual film development. For X-ray films, it is recommended to use Kodak's original Kodak X-OMAT BT film (FF057 / FF081) for biological experiments.
[0098] 2.4 Statistical methods and experimental results
[0099] Experimental groups: blank group, model group, positive group and treatment group; SPSsl3.0 software was used to perform statistical analysis on the quantitative data, and the quantitative data were expressed as mean ± standard deviation. The protein expression test was performed on rat knee cartilage. Western blot test results are shown in Figure 2 .
[0100] Figure 2 The results showed that compared with the normal group, the expression of BMPR, SMAD1 / 5 / 9, and CREB1 in the model group was significantly reduced, indicating that the modeling was successful; compared with the model group, the expression of BMPR, SMAD1 / 5 / 9, and CREB1 in the treatment group was significantly higher than that in the model group, and the expression of some molecules was higher than that in the positive control group; compared with the model group, the expression of BMPR, SMAD1 / 5 / 9, and CREB1 in the treatment group was significantly higher than that in the model group, and the expression of some molecules was higher than that in the positive control group, indicating that the treatment group has a good promoting effect on the regeneration of knee osteoarthritis and articular cartilage through the BMP signal transduction pathway. It can be concluded that the BMP signaling pathway can participate in the repair and regeneration of knee osteoarthritis and articular cartilage in the treatment group and the regeneration of new bone of osteogenesis and has a good promoting effect. Therefore, the composition in the treatment group can promote the regeneration of cartilage and new bone.
[0101] The present invention is not limited to the above-mentioned specific implementation modes. Various changes made by ordinary technicians in this field based on the above-mentioned concepts without creative work are all within the protection scope of the present invention.
Claims
1. A composition for promoting cartilage and new bone regeneration, characterized in that: It comprises Ca-MCP and medically acceptable pharmaceutical excipients, wherein the mass percentage of the Ca-MCP is 0.1-10%; The Ca-MCP is made by mixing achondrite, purple sand and clay in certain mass percentages, wherein the mass percentages of the achondrite, purple sand and clay are 0.3-43%: 56-95%: 1-5%; The medically acceptable pharmaceutical excipient is selected from a combination of liquid paraffin, xanthan gum, cetearyl alcohol, glycerin, monoglyceride, polydimethylsiloxane, and menthone glycerol ketal; The dosage form of the composition is a paste; The lead dissolution of the Ca-MCP is less than 0.1 mg / L, and the cadmium dissolution is less than 0.02 mg / L.
2. The method for preparing the composition for promoting cartilage and new bone regeneration according to claim 1, characterized in that: The method comprises: mixing Ca-MCP and medically acceptable pharmaceutical excipients to obtain the composition.
3. Use of the composition for promoting cartilage and new bone regeneration as claimed in claim 1 in the preparation of a drug for promoting cartilage and new bone regeneration.
